Skip to main content
Clinical Trials/EUCTR2016-002389-29-BE
EUCTR2016-002389-29-BE
Active, not recruiting
Phase 1

An Exploratory Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Respiratory Imaging (FRI) Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long Term Oxygen Therapy (LTOT).

Bellerophon Pulse Technologies, LLC0 sitesJune 28, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Bellerophon Pulse Technologies, LLC
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 28, 2016
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Bellerophon Pulse Technologies, LLC

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female patient
  • 2\. A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria
  • 3\. Pulmonary hypertension will be defined as sPAP \= 38 mmHg as determined by echocardiogram (not obtained within ± 7 days of an exacerbation) within the past 12 months.
  • 4\. Current or former smokers with at least 10 pack\-years of tobacco cigarette smoking before study entry
  • 5\. Age \= 40 years, \= 85 years
  • 6\. A post\-bronchodilatory FEV1/FVC \< 0\.7 and a FEV1 \< 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening)
  • 7\. Receiving LTOT for \= 3 months and \= 10 hours per day as determined by history
  • 8\. Females of childbearing potential must have a negative pre\-scan urine pregnancy test
  • 9\. Signed informed consent prior to the initiation of any study mandated procedures or assessments.
  • Are the trial subjects under 18? no

Exclusion Criteria

  • 1\. Males who have the intention to father a child during the study.
  • 2\. A diagnosis of asthma or other non\-COPD respiratory disease, in the opinion of the Investigator
  • 3\. Lack of patency of nares upon physical examination
  • 4\. Experienced during the last month an exacerbation requiring:
  • a) start of or increase in systemic oral corticosteroid therapy and/or
  • b) hospitalization
  • 5\. Left ventricular dysfunction as measured by:
  • a) Screening echocardiographic evidence of left ventricular systolic dysfunction (left ventricular ejection fraction \[LVEF] \< 40%), or
  • b) Screening echocardiographic evidence of left ventricular diastolic dysfunction \> moderate (i.e., \> Grade 3\), or
  • c) Any history of pulmonary capillary wedge pressure (PCWP), left atrial pressure (LAP) or left ventricular end diastolic pressure (LVEDP) \> 18 mmHg as measured during cardiac catheterization

Outcomes

Primary Outcomes

Not specified

Similar Trials